PL2734552T3 - Hamujące monoklonalne przeciwciała skierowane przeciwko czynnikowi xii/xiia i ich zastosowanie - Google Patents

Hamujące monoklonalne przeciwciała skierowane przeciwko czynnikowi xii/xiia i ich zastosowanie

Info

Publication number
PL2734552T3
PL2734552T3 PL12735916.4T PL12735916T PL2734552T3 PL 2734552 T3 PL2734552 T3 PL 2734552T3 PL 12735916 T PL12735916 T PL 12735916T PL 2734552 T3 PL2734552 T3 PL 2734552T3
Authority
PL
Poland
Prior art keywords
xiia
monoclonal antibodies
antibodies against
factor xii
against factor
Prior art date
Application number
PL12735916.4T
Other languages
English (en)
Inventor
Con Panousis
Veronika Rayzman
Andrew Nash
Michael Wilson
Stefan Schmidbauer
Marc Nolte
Original Assignee
Csl Behring Gmbh
Csl Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11175105A external-priority patent/EP2548892A1/en
Application filed by Csl Behring Gmbh, Csl Limited filed Critical Csl Behring Gmbh
Publication of PL2734552T3 publication Critical patent/PL2734552T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21038—Coagulation factor XIIa (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
PL12735916.4T 2011-07-22 2012-07-20 Hamujące monoklonalne przeciwciała skierowane przeciwko czynnikowi xii/xiia i ich zastosowanie PL2734552T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161510801P 2011-07-22 2011-07-22
EP11175105A EP2548892A1 (en) 2011-07-22 2011-07-22 Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
EP12153310 2012-01-31
PCT/EP2012/064322 WO2013014092A1 (en) 2011-07-22 2012-07-20 Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses

Publications (1)

Publication Number Publication Date
PL2734552T3 true PL2734552T3 (pl) 2025-03-24

Family

ID=47600530

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12735916.4T PL2734552T3 (pl) 2011-07-22 2012-07-20 Hamujące monoklonalne przeciwciała skierowane przeciwko czynnikowi xii/xiia i ich zastosowanie

Country Status (26)

Country Link
US (5) US9518127B2 (pl)
EP (2) EP2734552B1 (pl)
JP (1) JP6253578B2 (pl)
KR (1) KR102042982B1 (pl)
CN (1) CN103687878B (pl)
AU (1) AU2012289001B2 (pl)
BR (1) BR112014001104B1 (pl)
CA (1) CA2841185C (pl)
DK (1) DK2734552T3 (pl)
ES (1) ES3005912T3 (pl)
FI (2) FI2734552T3 (pl)
FR (1) FR25C1026I1 (pl)
HR (1) HRP20250164T1 (pl)
HU (2) HUE070002T2 (pl)
IL (2) IL230564B2 (pl)
LT (2) LT2734552T (pl)
MX (1) MX347454B (pl)
NL (1) NL301332I2 (pl)
NO (1) NO2025031I1 (pl)
PL (1) PL2734552T3 (pl)
PT (1) PT2734552T (pl)
RS (1) RS66465B1 (pl)
RU (1) RU2660370C2 (pl)
SI (1) SI2734552T1 (pl)
SM (1) SMT202500041T1 (pl)
WO (1) WO2013014092A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841185C (en) * 2011-07-22 2021-05-25 Csl Behring Gmbh Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
AU2014224599B2 (en) * 2013-03-08 2018-11-08 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
JP2017501968A (ja) 2013-06-28 2017-01-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
US20170114119A1 (en) 2014-06-18 2017-04-27 Csl Behring Gmbh Therapy using a factor xii inhibitor in a neurotraumatic disorder
CA2972800A1 (en) 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
US10913802B2 (en) * 2015-07-21 2021-02-09 Dyax Corp. Monoclonal antibody inhibitor of factor XIIA
MA43660A (fr) * 2016-01-22 2018-11-28 Adimab Llc Anticorps anti-facteur xi de coagulation
CA3019851A1 (en) * 2016-04-06 2017-10-12 Csl Limited Method of treating atherosclerosis
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
JP7317827B2 (ja) * 2017-12-15 2023-07-31 シーエスエル、リミテッド 腎線維症および／または慢性腎臓疾患の治療におけるＦＸＩＩａインヒビターの使用
EA202190056A1 (ru) 2018-06-19 2021-05-28 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ
WO2020113084A1 (en) * 2018-11-28 2020-06-04 Oregon Health & Science University Therapeutic factor xii antibody
BR112021024788A2 (pt) * 2019-06-12 2022-04-19 CSL Innovation Pty Ltd Conjugados de variante de receptor de complemento solúvel tipo 1 e usos dos mesmos
JP7709970B2 (ja) * 2019-12-03 2025-07-17 シーエスエル・イノベーション・プロプライエタリー・リミテッド 遺伝性血管性浮腫の治療または予防のための抗第ｘｉｉ因子抗体の使用
US20240352150A2 (en) * 2020-06-16 2024-10-24 Ningbo Comgen Biotech Co., Ltd. Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof
AU2021302684A1 (en) * 2020-07-03 2023-02-23 CSL Innovation Pty Ltd High concentration formulation of factor XII antigen binding proteins
CN116265945B (zh) * 2022-01-05 2025-12-09 上海迈晋生物医药科技有限公司 抗凝血药物的生物学活性检测方法
WO2024255794A1 (zh) * 2023-06-16 2024-12-19 舒泰神（北京）生物制药股份有限公司 特异性识别因子XIIa的抗体及其应用
WO2025019789A1 (en) 2023-07-19 2025-01-23 Regeneron Pharmaceuticals, Inc. ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8901859D0 (en) * 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
EP0534988A1 (en) * 1990-05-10 1993-04-07 Cetus Corporation Inhibitors of factor xii activation and applications thereof
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
CA2106079C (en) 1991-03-15 2000-04-25 Robert C. Thompson Pegylation of polypeptides
JPH11501506A (ja) 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7112661B1 (en) * 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
US7414170B2 (en) * 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
US7074983B2 (en) * 1999-11-19 2006-07-11 Kirin Beer Kabushiki Kaisha Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
US20040077538A1 (en) 2000-05-17 2004-04-22 Harvey Pollard Use of factor XIIa for treatment of hemophilia A and B and prevention of bleeding
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
KR20060088905A (ko) * 2000-06-16 2006-08-07 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
AU2003290689A1 (en) * 2002-11-08 2004-06-03 Kyowa Hakko Kirin Co., Ltd. Transgenic ungulates having reduced prion protein activity and uses thereof
CA2511125A1 (en) * 2002-12-20 2004-07-08 Axis-Shield Diagnostics Limited Detection or determination of variants of factor xiia
GB0229837D0 (en) * 2002-12-20 2003-01-29 Axis Shield Diagnostics Ltd Variants of activated factor XII
HUE026384T2 (en) 2003-05-06 2016-06-28 Biogen Hemophilia Inc VII coagulation factor-FC chimeric proteins for the treatment of hemostasis disorder
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ATE525395T1 (de) 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
AU2004266246A1 (en) * 2003-08-14 2005-03-03 Dyax Corp. Endotheliase-2 ligands
CA2537273A1 (en) 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
EP1598428A1 (en) * 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
JP2008515774A (ja) * 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
JP5118492B2 (ja) 2004-12-23 2013-01-16 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 血栓の形成の防止および／または安定化の防止
GB0500487D0 (en) 2005-01-11 2005-02-16 Axis Shield Diagnostics Ltd Forms of factor XIIa
GB0607515D0 (en) * 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
CA3154415A1 (en) 2006-10-10 2008-04-17 Regenesance B.V. Anti-sense oligonucleotide for use in facilitating axonal regeneration
KR101629702B1 (ko) 2007-02-12 2016-06-13 체에스엘 베링 게엠베하 카잘-형 세린 프로테아제 억제제의 치료학적 적용
US20080199481A1 (en) 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
US8114968B2 (en) * 2008-03-03 2012-02-14 Dyax Corp. Metalloproteinase-12 specific monoclonal antibody
MX2011005481A (es) * 2008-11-25 2011-08-17 Biogen Idec Inc Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
EP3482769B1 (en) 2008-12-19 2024-05-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2385843A4 (en) * 2009-01-06 2013-02-27 Dyax Corp TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
CA2750533A1 (en) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
EP4011917A1 (en) * 2010-01-06 2022-06-15 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
AU2012204202A1 (en) * 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
CA2841185C (en) * 2011-07-22 2021-05-25 Csl Behring Gmbh Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses

Also Published As

Publication number Publication date
US9856326B2 (en) 2018-01-02
SI2734552T1 (sl) 2025-03-31
LTPA2025524I1 (pl) 2025-07-10
US20200062863A1 (en) 2020-02-27
US9856325B2 (en) 2018-01-02
NL301332I2 (nl) 2025-09-10
WO2013014092A1 (en) 2013-01-31
FIC20250024I1 (fi) 2025-07-08
PT2734552T (pt) 2025-01-29
MX2014000363A (es) 2014-03-27
FI2734552T3 (fi) 2025-02-12
HUE070002T2 (hu) 2025-04-28
DK2734552T3 (da) 2024-12-09
AU2012289001B2 (en) 2016-03-03
NO2025031I1 (no) 2025-07-09
CN103687878B (zh) 2018-01-09
KR20140054112A (ko) 2014-05-08
JP6253578B2 (ja) 2017-12-27
US20170137536A1 (en) 2017-05-18
CA2841185A1 (en) 2013-01-31
HK1198334A1 (en) 2015-04-02
RS66465B1 (sr) 2025-02-28
CN103687878A (zh) 2014-03-26
MX347454B (es) 2017-04-27
LT2734552T (lt) 2025-01-10
KR102042982B1 (ko) 2019-11-11
SMT202500041T1 (it) 2025-03-12
EP2734552A1 (en) 2014-05-28
IL230564B2 (en) 2023-09-01
IL230564B1 (en) 2023-05-01
US11345759B2 (en) 2022-05-31
US20140199361A1 (en) 2014-07-17
EP2734552B1 (en) 2024-11-13
JP2014523253A (ja) 2014-09-11
IL230564A0 (en) 2014-03-31
NZ619385A (en) 2016-07-29
CA2841185C (en) 2021-05-25
US9518127B2 (en) 2016-12-13
HRP20250164T1 (hr) 2025-04-11
AU2012289001A1 (en) 2013-05-02
EP4516811A2 (en) 2025-03-05
IL291613B2 (en) 2025-12-01
BR112014001104A2 (pt) 2017-12-12
US20170121423A1 (en) 2017-05-04
FR25C1026I1 (fr) 2025-09-19
RU2660370C2 (ru) 2018-07-05
EP4516811A3 (en) 2025-03-26
US20180134806A1 (en) 2018-05-17
US10513560B2 (en) 2019-12-24
HUS2500028I1 (hu) 2025-07-28
IL291613A (en) 2022-05-01
IL291613B1 (en) 2025-08-01
ES3005912T3 (en) 2025-03-17
RU2014106652A (ru) 2015-08-27
BR112014001104B1 (pt) 2022-12-06

Similar Documents

Publication Publication Date Title
PL2734552T3 (pl) Hamujące monoklonalne przeciwciała skierowane przeciwko czynnikowi xii/xiia i ich zastosowanie
HUS2300021I1 (hu) Anti-IL-36R antitestek
LTPA2021001I1 (lt) Anti-PD-L1 antikūnai ir jų panaudojimas
DK3842456T3 (da) Monoklonalt Interleukin-31-antistof
DK2521736T3 (da) Humaniserede antistoffer
IL249650A0 (en) Antibodies directed against icos and uses thereof
IL231777B (en) Antibodies against tl1a and uses thereof
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
IL221408B (en) Monoclonal antibodies against c-met
DK2668210T3 (da) Anti-kit antistoffer og anvendelser deraf
BR112013022797A2 (pt) anticorpos anti-ctla4 humanizados
PL2731677T3 (pl) Przeciwciała wiążące się z OX40 i ich zastosowania
CO6811812A2 (es) Anticuerpo anti-b7-h3
DK2683406T3 (da) Anti-cd40-antistoffer og anvendelser deraf
BR112014010198A2 (pt) Anticorpos humanizados que reconhecem alfa- sinucleína
LT3284754T (lt) Antikūnai prieš cd38
CR20140127A (es) Anticuerpo anti-abtcr
BR112013002297A2 (pt) anticorpos humanizados seguros e funcionais
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
LT2742068T (lt) Nauji antikūnai prieš fosforilcholiną
CO6841994A2 (es) Anticuerpos